I specialize in economic evaluations, business strategy, public health, and market research. With a diverse international background—having lived and worked in Argentina, Mexico City, the United State ...
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report). The company’s shares opened today at $1.95. According ...
The lowered price target reflects these complex factors as the company moves forward with its ALS treatment research. In other recent news, BrainStorm Cell Therapeutics Inc. successfully regained ...